Line 24 Quiz

Create an informative and engaging illustration depicting various diabetic medications and cardiovascular drugs, with a clear focus on their mechanisms of action and indications, set in a clinical environment.

Diabetes and Cardiovascular Pharmacotherapy Quiz

Test your knowledge on diabetes management and cardiovascular pharmacotherapy with our comprehensive quiz! This quiz includes 45 carefully crafted questions that cover various aspects of drug indications, mechanisms of action, and clinical applications.

  • Explore the latest treatment guidelines.
  • Challenge your understanding of medication mechanisms.
  • Boost your pharmacological knowledge!
45 Questions11 MinutesCreated by LearningDoctor752
In diabetic patients; to consider monotherapy with Metformin , patient HbA1c must be 
Less than 9%
More than 9%
9 - 10 %
Mechanism of action of Andorivaban 
Direct factor Xa inhibitor
Indirect factor Xa inhibitor
Prevent thrombin formation
Prevent platelet aggregation
Andouristat tablets are scored 
True
False
Protectopril plus is 
Cardio protective
Decrease incidence of stroke
Both 1 and 2
Record trial compared Rivaroxban with Low molecular weight heparin (Enoxparin)
True
False
Andouristat differ from other Febouxstat in double aluminium packaging
True
False
Protectopril is Perindopril Arginine while Coversyl is Perindopril Erbumine
True
False
Andoglycemic 1000 mg can be taken as 
Once daily
Twice daily
Two tablets as one shot in case of 2 gm
Twice daily in case of 2 gm
Andorivaban should be stopped before surgery by 
12 hours
72 hours
24 -  48 hours 
Andouristat mechanism of action
Xanthine Oxidase Inhibitor
Xanthine dehydrogenase inhibitor
Both 1 and 2
Indication of Protectopril 
Mild hypertension
Mild to moderate hypertension
Severe hypertension
Andoglycemic 1000 mg monthly cost is 
24 L.E
60 L.E
36 L.E
Andorivaban 2.5 class in ESC 2019  is 
IIa
IIb
Ia
Andouristat act on 5 Enzymes , while Allopurinol act on 1 Enzyme
True
False
Main Competitor for Protectopril is Coversyl and it's price 90 L.E
True
False
FDA approved Indication of Andoglycemic 
Prediabetic
Type II diabetes 
Type 1 diabetes 
Losing weight
Indication of Andorivaban 2.5 is
Chronic coronary arterial disease 
Acute coronary arterial disease 
Chronic peripheral arterial disease
Acute peripheral arterial disease
Andouristat has a linear pharmacokinetics from 10 - 240 mg
True
False
Protectopril is an ACE inhibitor
True
False
Andoglycemic main competitor is Glucophage XR and it's monthly cost is 60 L.E
True
False
Andouristat dose is 80 mg taken twice daily and may be increased to 120 mg after 1 month
True
False
Protectopril 8 mg is scored 
True
False
Protectopril dose is taken
Once daily 
Twice daily
Once or Twice
Protectopril plus is Perindopril with
Indapamide
Hydrochlorothiazide
Calcium channel blocker
Indication of Andorivaban 10 mg in Orthopedics
Total hip replacement
Total Knee replacment 
Immobilized patients
Which drug is more tolerable  ?
Glucophage intermediate release 
Cidophage Retard
Andoglycemic extended release 
Andorivaban 10 mg price is 152 L.E , while Andorivaban 2.5 mg monthly cost is 180 L.E
True
False
Protectopril price is 44 L.E , while Protectopril plus price is 32 L.E
True
False
Target Serum uric acid 
Less 6%
6 - 7 %
More than 8%
Andouristat 80 mg price is 56 L.E , while Andouristat 120 mg price is 62 L.E
True
False
To consider dual therapy for diabetic patients , HbA1c should be 
Less than 9%
9% - 10%
More than 10 %
Normal HbA1c level 
Less than 5.7 %
5.7 % - 6.4 %
More than 10 %
Spacing between Andorivaban and NSAIDs should be
2 - 3 hours
4 - 6  hours
6 - 8 hours
Andoglycemic XR affect which parameter 
FPG and PPG
HOMA - IR
HbA1c
All the above
Duration of Andorivaban in patients with Total hip replacement is 5 week , while Total knee replacement 2 week
True
False
Fasting Plasma Glucose (FPG) normal is
Less than 100 mg/dl
100 - 125 mg/dl
More than 125 mg/dl
Perfect age to use Andorivaban  2.5 mg
Less than 45 years
45 - 65 years
More than 65 years
Prediabetic Post prandial Plasma Glucose (PPG)   level is 
Less than 140 mg/dl
140 - 180 mg/dl
More than 180 mg/dl 
The Result of Record 1 79 % RRR in total VTE , while Record 2 70%
True
False
In Compass trial MI decreased by 14 % while major CVS events decreased by 24%
True
False
In hazard trial Heart disease increase by
2.5 fold
3 fold
3.6 fold
8.5 fold
In compass trial stroke decreased without any significant bleeding by RRR
42%
28%
44%
24%
In Record trial Andorivaban shows lower risk in bleeding than Enoxparin
True
False
In Compass trial; the acute limb ischemic attacks decreases amputation by 77%
True
False
In hazard trial; the liver disease increase by 8.5 folds
True
False
{"name":"Line 24 Quiz", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"Test your knowledge on diabetes management and cardiovascular pharmacotherapy with our comprehensive quiz! This quiz includes 45 carefully crafted questions that cover various aspects of drug indications, mechanisms of action, and clinical applications.Explore the latest treatment guidelines.Challenge your understanding of medication mechanisms.Boost your pharmacological knowledge!","img":"https:/images/course2.png"}
Powered by: Quiz Maker